EFFECT OF RIFAMPIN INDUCTION ON THE GLUCOSELOWERING EFFECT OF METFORMIN AND OCT1 MRNA LEVELS IN HEALTHY PARTICIPANTS.
GENETIC POLYMORPHISMS RELATED TO PACILTAXELINDUCED CYTOTOXICITY IN LYMPHOBLASTOID CELL LINES AND OVERALL SURVIVAL IN LUNG CANCER PATIENTS AFTER PACLITAXEL-BASED CHEMOTHERAPY.
GLYCINE AND A GLYCINE DEHYDROGENASE (GLDC) SNP AS SSRI RESPONSE BIOMARKERS IN DEPRESSION: PHARMACOMETABOLOMICS- INFORMED PHARMACOGENOMICS.
INTERACTION BETWEEN GENETIC VARIANTS IN THE TRANSPORTERS, OCT1 AND MATE1, AND GLYCEMIC RESPONSE TO METFORMIN.
THE IN VITRO PLATELET TOXICITY ASSAY (iPTA): VALIDATION OF A NOVEL DIAGNOSTIC TEST FOR DRUG HYPERSENSITIVITY SYNDROME.
POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (POP PK/PD) MODELING OF PF-04929113 MEDIATED EFFECTS ON HEAT SHOCK PROTEIN (HSP) 70 IN CANCER PATIENTS (PTS).
ASSOCIATION OF INFLIXIMAB CLEARANCE AND RESTING ENERGY EXPENDITURE IN CHILDREN.
A TOOL FOR DRUG INDIVIDUALIZATION: VALIDATION OF A TRANSCRIPTIONAL PROFILE OF TOLERANCE IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS.
STEM CELL INTERVENTION AT PRE-SYMPTOMATIC STAGE PREVENTS OVERT HEART FAILURE SYNDROME IN GENETIC CARDIOMYOPATHY.
IN VIVO CYP3A-ACTIVITY IS SIGNIFICANTLY LOWER IN CYCLOSPORINE THAN IN TACROLIMUS TREATED RENAL TRANSPLANT RECIPIENTS.
GENETIC MARKERS ASSOCIATED WITH PLATINUM/TAXANES INDUCED GASTROINTESTINAL TOXICITY IN SCOTROC1 TRIAL.
EFFECT OF GENETIC VARIATION IN THE ORGANIC CATION TRANSPORTER 1 AND 2 ON METFORMIN PHARMACOKINETICS: NONLINEAR MIXED EFFECTS ANALYSIS.
CONTRIBUTION OF OATP1B-TYPE CARRIERS TO CISPLATIN DISPOSITION AND TOXICITY.
THE CYP3A5 GENOTYPE HAS A MARKED IMPACT ON TACROLIMUS PHARMACOKINETICS BUT DOES NOT AFFECT MIDAZOLAM PHARMACOKINETICS IN A LARGE COHORT OF RENAL TRANSPLANT RECIPIENTS.
THE URINE CONCENTRATION RATIO OF EXPERIMENTERADMINISTERED DEUTERIUM LABELED METHAMPHETAMINE TO UNLABELED METHAMPHETAMINE - A NOVEL QUANTITATIVE METHOD TO QUANTIFY THE AMOUNT OF ILLICIT DRUG USE.
CYCLOOXYGENASE-2 (COX-2) AND IMPAIRED RESPONSE TO ASPIRIN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.
GRAPEFRUIT JUICE INCREASES SYSTEMIC EXPOSURE OF LOPERAMIDE WITHOUT CONSEQUENT CENTRAL NERVOUS SYSTEM OPIATE-LIKE EFFECTS IN HEALTHY VOLUNTEERS.
GLYCINE AND A GLYCINE DEHYDROGENASE (GLDC) SNP AS SSRI RESPONSE BIOMARKERS IN DEPRESSION: PHARMACOMETABOLOMICS- INFORMED PHARMACOGENOMICS.
THE IN VITRO PLATELET TOXICITY ASSAY (iPTA): VALIDATION OF A NOVEL DIAGNOSTIC TEST FOR DRUG HYPERSENSITIVITY SYNDROME.
A TOOL FOR DRUG INDIVIDUALIZATION: VALIDATION OF A TRANSCRIPTIONAL PROFILE OF TOLERANCE IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS.
POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (POP PK/PD) MODELING OF PF-04929113 MEDIATED EFFECTS ON HEAT SHOCK PROTEIN (HSP) 70 IN CANCER PATIENTS (PTS).
THE DIFFERENT EFFECT OF CYP2C19 GENOTYPE OVER TIME ON PHARMACOKINETICS AND PHARMACODYNAMICS OF CLOPIDOGREL AND ITS ACTIVE METABOLITE.
THE CARDIOVASCULAR OUTCOMES ASSOCIATED WITH CONCOMITANT USE OF CLOPIDOGREL AND PROTON PUMP INHIBITORS IN PATIENTS OF ACUTE CORONARY SYNDROME IN TAIWAN - A POPULATION-BASED COHORT STUDY.
RISK OF CARDIOVASCULAR EVENTS IN A REAL-WORLD POPULATION OF 86,564 PATIENTS RECEIVING CONCOMITANT CLOPIDOGREL AND PROTON PUMP INHIBITOR THERAPY.
RISK OF RECURRENT MYOCARDIAL INFARCTION WITH THE CONCOMITANT USE OF CLOPIDOGREL AND PROTON PUMP INHIBITORS.
PI-01
APPLICATION OF A DIAGNOSTIC TECHNIQUE FOR ASSESSMENT OF THE EFFECT OF GLP-1 ANALOGUES / AGONISTS ON GALLBLADDER EMPTYING.
VALIDATION AND FURTHER QUALIFICATION OF THE HISTAMINE INDUCED PRURITUS MODEL IN HEALTHY HUMAN VOLUNTEERS AS A TOOL IN EARLY DRUG DEVELOPMENT.
THE URINE CONCENTRATION RATIO OF EXPERIMENTERADMINISTERED DEUTERIUM LABELED METHAMPHETAMINE TO UNLABELED METHAMPHETAMINE—A NOVEL QUANTITATIVE METHOD TO QUANTIFY THE AMOUNT OF ILLICIT DRUG USE.
LACK OF A MEANINGFUL EFFECT OF ANACETRAPIB ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF WARFARIN IN HEALTHY SUBJECTS.
LACK OF A MEANINGFUL EFFECT OF ANACETRAPIB ON THE PHARMACOKINETICS OF DIGOXIN IN HEALTHY SUBJECTS.
COMPARISON OF SIX COMMONLY USED QT CORRECTION FORMULAE AND THREE PARAMETER ESTIMATION METHODS.
COMPARISON OF DIGITAL 12-LEAD ECG AND DIGITAL 12-LEAD HOLTER ECG RECORDINGS IN HEALTHY MALE SUBJECTS.
QUANTITATIVE AND TEMPORAL SHIFT IN BLOOD PRESSURE IN PATIENTS AFTER SWITCHING TO A DIFFERING NIFEDIPINE OSMOTIC DELIVERY DESIGN.
THE FIRST ORALLY ADMINISTERED LOW MOLECULAR WEIGHT LH AGONIST INDUCES OVULATION IN HEALTHY YOUNG WOMEN.
CLINICAL PHARMACOLOGY OF T-DM1: A NOVEL ANTIBODY- DRUG CONJUGATE (ADC) IN DEVELOPMENT FOR THE TREATMENT OF HER2-POSITIVE (HER2+) CANCER.
EXPLORING GENDER DIFFERENCES IN QTCF RESPONSE TO MOXIFLOXACIN IN A RANDOMIZED, DOUBLE BLIND STUDY.
SINGLE- AND MULTIPLE-DOSE PHARMACOKINETICS OF THE NEW FORMULATION OF AMOXICILLIN/CLAVULANIC ACID (10:1) INJECTION IN HEALTHY VOLUNTEERS.
PHARMACOKINETICS AND PHARMACODYNAMICS OF DA-1229, A NOVEL DIPEPTIDYL PEPTIDASE (DPP) IV INHIBITOR, AFTER SINGLE OR MULTIPLE DOSING IN HEALTHY VOLUNTEERS.
NARCOTIC USE DOES NOT DECREASE AFTER INITIATION OF DMARD THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS.
DRUGS THAT MAY CAUSE HEADACHE OR AGGRAVATE MIGRAINE IN VETERANS REFERRED TO A TRANSCRANIAL DOPPLER LABORATORY.
SIBUTRAMINE-ASSOCIATED CARDIOVASCULAR TOXICITY: IS IT INVOLVING THE QT INTERVAL?
DRUG BURDEN INDEX AND BEERS CRITERIA: IMPACT ON FUNCTION IN OLDER ADULTS LIVING IN LOW-LEVEL CARE FACILITIES.
A REVIEW OF DUR METHODS REPORTED IN THE LITERATURE.
A PROSPECTIVE, SINGLE-BLIND, PLACEBO- CONTROLLED, RANDOMIZED, CROSSOVER STUDY TO ASSESS THE PERFORMANCE OF AUTOMATED AND MANUAL METHODOLOGIES FOR DETECTING QTC INTERVAL PROLONGATION.
TIZANIDINE: A MUSCLE RELAXANT THAT MAY PROLONG THE QT INTERVAL BY BLOCKING IKR.
INHIBITORY EFFECT OF EFAVIRENZ ON CYP2C8-CATALYZED AMODIAQUINE N-DESETHYLATION IN VITRO.
INTERPRETATION OF EPITHELIAL LINING FLUID CONCENTRATIONS OF ANTIBIOTICS AGAINST METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS.
PI-24
GENETIC VARIATION IN CATECHOLAMINE PATHWAYS IS ASSOCIATED WITH PLASMA NOREPINEPHRINE CONCENTRATION.
GENETIC VARIATION IN CATECHOLAMINE PATHWAYS AND RESPONSE TO A BETA-ADRENERGIC RECEPTOR ANTAGONIST.
IMPACT OF CYP2C19 GENOTYPES AND EFAVIRENZ ON STEREOSELECTIVE METABOLISM OF OMEPRAZOLE IN HEALTHY VOLUNTEERS.
CYP4F2 GENETIC POLYMORPHISMS INFLUENCE WARFARIN DOSE REQUIREMENTS IN POLYMEDICATED PATIENTS INITIATING WARFARIN THERAPY.
IDENTIFICATION AND COMPARATIVE ANALYSIS OF GENETIC VARIATIONS IN UDP-GLUCUROSYLTRANSFERASE 2B7 GENE (UGT2B7) IN KOREANS AND OTHER ETHNIC POPULATIONS.
A HAPLOTYPE OF P2Y12 GENE ASSOCIATED WITH THE INCREASED RESPONSES TO ADP-INDUCED PLATELET AGGREGATION.
THE EVALUATION OF THE RELATIONSHIP BETWEEN CHEMOSENSITIVITY TESTING, PROTEIN ASSAY AND FIRST REMISSION RESPONSE IN KOREAN LEUKEMIC PATIENTS.
PI-32
DEVELOPMENT OF PHARMACOGENETIC TESTS.
EFFECTS OF CLOPIDOGREL, CYP2B6 AND CYP2C19 INHIBITORS, ON THE PHARMACOKINETICS OF SIBUTRAMINE AND ITS ACTIVE METABOLITES.
THE METABOLISM OF 1'- AND 4-HYDROXYMIDAZOLAM BY GLUCURONIDE CONJUGATION IS MAINLY MEDIATED BY UDP-GLUCURONOSYLTRANSFERASES 1A4, 2B4, AND 2B7.
PI-36
CYP2C9*2 PREDICTS BOSENTAN INDUCED LIVER INJURY.
EXPLORATORY ASSESSMENT OF THE DRUG-DRUG INTERACTION (DDI) RISK USING SIMCYP AND POPULATION PK SIMULATION FOR THE PAN-PHOSPHOINOSITIDE-3 KINASE (PI3K) INHIBITOR GDC-0941, A POTENTIAL CYP2C8 INHIBITOR.
GENETIC VARIATION IN THE CALCIUM SIGNALING PATHWAY AND ASSOCIATION WITH OUTCOMES IN HYPERTENSIVE CORONARY ARTERY DISEASE PATIENTS.
EVALUATION OF THE PHARMACODYNAMICS AND PHARMACOKINETICS OF THE INTERACTION OF LU AA21004 AND ETHANOL IN HEALTHY ADULT SUBJECTS.
THE EFFECT OF VOGLIBOSE ON THE DISPOSITION OF METFORMIN AFTER THE MULTIPLE ADMINISTRATION OF VOGLIBOSE AND METFORMIN IN HEALTHY SUBJECTS.
THE PHARMACODYNAMIC INTERACTION BETWEEN VOGLIBOSE AND METFORMIN AFTER THE MULTIPLE ADMINISTRATION OF VOGLIBOSE AND METFORMINE IN HEALTHY SUBJECTS.
PHASE I, OPEN-LABEL, DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF KETOCONAZOLE ON SINGLE DOSE MIRABEGRON (YM178) ORAL CONTROLLED ABSORPTION SYSTEM (OCAS) IN HEALTHY ADULT SUBJECTS.
PHASE I, OPEN-LABEL, DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF REPEAT DOSES OF RIFAMPIN ON THE SINGLE-DOSE PHARMACOKINETICS OF MIRABEGRON (YM178) IN HEALTHY ADULT SUBJECTS.
CO-ADMINISTRATION OF QUERCETIN AND WARFARIN: EVALUATION OF POTENTIAL NUTRIENT-DRUG INTERACTION INVOLVING CYP2C9.
CO-ADMINISTRATION OF QUERCETIN AND DIGOXIN: EVALUATION OF POTENTIAL NUTRIENT-DRUG INTERACTION INVOLVING THE P-GLYCOPROTEIN TRANSPORTER.
EFFECT OF CO-ADMINISTRATION OF MULTIPLE-DOSE TACROLIMUS AND CYCLOSPORINE ON THE PHARMACOKINETICS OF TASOCITINIB (CP-690,550) IN HEALTHY VOLUNTEERS.
EPOPROSTENOL WITH IMPROVED STABILITY HAS SAME PHARMACOKINETIC AND PHARMACODYNAMIC PROFILES AS STANDARD EPOPROSTENOL IN HEALTHY SUBJECTS.
EVALUATION OF A SEMI-MECHANISTIC MODEL TO DESCRIBE REDUCTIONS IN NEUTROPHIL COUNTS FOLLOWING TASOCITINIB (CP-690,550) ADMINISTRATION TO RHEUMATOID ARTHRITIS (RA) PATIENTS.
PHARMACOKINETICS OF ORAL CYCLOPHOSPHAMIDE IN CHILDHOOD STEROID-SENSITIVE NEPHROTIC SYNDROME.
THE PREDICTED AND OBSERVED EFFECT OF STEADYSTATE ADMINISTRATION OF KETOCONAZOLE ON THE METABOLISM OF GSK962040 ASSESSED USING NOVEL METHODOLOGY.
A PHYSIOLOGY BASED MODEL FOR THE PHARMACOKINETIC BEHAVIOUR OF INTRAVENOUS AMIODARONE AS A BASIS FOR AN AGE APPROPRIATE DOSING REGIMEN FOR CHILDREN.
DRUG EFFECTS ON THE CARDIOVASCULAR SYSTEM DEVELOPMENT OF A MECHANISM-BASED PHARMACODYNAMIC MODEL TO IMPROVE TRANSLATION DRUG RESEARCH.
TYPE I AND TYPE II DIABETES: TWO DIFFERENT DISEASES, TWO DIFFERENT MODULATING EFFECTS ON CYP3A.
COMPARISON OF MODEL BASED PREDICTIONS OF THE MIDAZOLAM KETOCONAZOLE INTERACTION.
POPULATION PHARMACOKINETICS OF MAPK KINASE (MEK) INHIBITOR GDC-0973 IN PHASE I PATIENTS WITH SOLID TUMORS.
PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF VX-809 IN CYSTIC FIBROSIS SUBJECTS HOMOZYGOUS FOR THE F508DEL MUTATION.
CASE STUDY OF AN ADVERSE REACTION TO METHADONE DURING COADMINISTRATION OF LETROZOLE.
EFFECT OF CONCOMITANTLY ADMINISTERED KETOCONAZOLE ON PHARMACOKINETICS OF ORALLY ADMINISTERED BMS-690514, AN ErbB/VEGFR INHIBITOR, IN HEALTHY SUBJECTS.
EFFECT OF VARIOUS DEGREES OF RENAL IMPAIRMENT (RI) ON THE PHARMACOKINETICS (PK) OF SULOPENEM AFTER IV AND ORAL ADMINISTRATION.
PREDNISONE DOES NOT LEAD TO A SIGNIFICANT INDUCTION OF CYP3A4. E.
USE OF POPULATION MODELING & SIMULATION APPROACH TO INFORM DOSE AND REGIMEN SELECTION IN EARLY DRUG DEVELOPMENT.
POPULATION PHARMACOKINETICS OF ESLICARBAZEPINE ACETATE IN PATIENTS WITH PARTIAL-ONSET SEIZURES.
COADMINISTRATION OF COLCHICINE WITH THE POTENT P-GP AND CYP3A4 INHIBITOR, KETOCONAZOLE, SUBSTANTIALLY INCREASES COLCHICINE EXPOSURE.
EXPOSURE-RESPONSE ANALYSIS OF ESLICARBAZEPINE ACETATE ADJUNCTIVE TREATMENT OF PATIENTS WITH PARTIAL-ONSET SEIZURES.
THE CONTRIBUTION OF CYP3A ENZYMES TO THE SINGLE AND MULTIPLE DOSE ORAL CLEARANCE OF THE AUTOINDUCER SEMAGACESTAT.
PHARMACOKINETICS OF DEPOBUPIVACAINE (EXPARELTM), A NOVEL BUPIVACAINE EXTENDED-RELEASE LIPOSOMAL INJECTION, IN VOLUNTEERS WITH MODERATE HEPATIC IMPAIRMENT.
POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF CONTROLLED-RELEASE CARVEDILOL CAPSULE IN HEALTHY VOLUNTEERS.
THE EFFECTS OF KETOCONAZOLE AND RIFAMPICIN ON THE PHARMACOKINETICS OF FIMASARTAN IN HEALTHY VOLUNTEERS.
INFLUENCE OF ROUX-EN-Y GASTRIC BYPASS SURGERY ON THE DISPOSITION OF PARACETAMOL, TALINOLOL AND AMOXICILLIN IN OBESE PATIENTS.
EFFECTS OF FIMASARTAN, A NOVEL ANGIOTENSIN II RECEPTOR BLOCKER, ON THE PHARMACOKINETICS OF ATORVASTATIN AND ITS METABOLITES IN HEALTHY VOLUNTEERS.
EFFECTS OF FIMASARTAN ON THE PHARMACOKINETICS AND SAFETY OF DIGOXIN IN HEALTHY MALE VOLUNTEERS.
EVALUATION OF PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF GCPGC, A NOVEL PEGYLATED G-CSF IN HEALTHY VOLUNTEERS.
THE EFFECT OF FIMASARTAN, A NOVEL ANGIOTENSIN RECEPTOR TYPE 1 (AT1) BLOCKER, ON THE PHARMACODYNAMICS, PHARMACOKINETICS, AND SAFETY OF WARFARIN IN HEALTHY MALE VOLUNTEERS.
DURATION OF ORAL BIOABAILABILITY ENHANCEMENT OF LOPERAMIDE BY HM30181AK, A NOVEL P-GLYCOPROTEIN INHIBITOR, IN HEALHTY KOREAN MALE SUBJECTS.
SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ASCENDING SINGLE ORAL DOSES OF CC-930, A NOVEL JNK INHIBITOR, IN HEALTHY SUBJECTS.
CONSUMPTION OF GRAPEFRUIT OR SEVILLE ORANGE JUICE DOES NOT AFFECT THE PHARMACOKINETICS OF COLCHICINE.
EFFECTS OF MACROLIDE ANTIBIOTICS AZITHROMYCIN AND CLARITHROMYCIN ON THE PHARMACOKINETICS OF COLCHICINE.
TREATMENT FOR SEVERE RESTLESS LEGS SYNDROME IN THE ELDERLY REDUCES THE RISK OF PROGRESSION OF ATRIAL FIBRILLATION.
EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF LURASIDONE.
ESTIMATION OF CREATININE CLEARANCE (ECLCR) ACROSS ALL WEIGHT STRATA.
VARIABILITY OF TACROLIMUS BLOOD LEVELS INCREASES THE RISK FOR GRAFT REJECTION IN SOLID ORGAN PEDIATRIC RECIPIENTS.
COMPARISON OF A DELAYED-RELEASE COMBINATION OF DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE (DICLECTIN®) PHARMACOKINETICS IN PREGNANT VS. NON-PREGNANT WOMEN.
DEVELOPMENTAL EXPRESSION OF NFAT5 IN PRENATAL HUMAN LIVER.
AGE AND CYP3A5 GENOTYPE AFFECT TACROLIMUS DOSING REQUIREMENTS DIRECTLY AFTER TRANSPLANT IN PEDIATRIC HEART RECIPIENTS.
RENAL FUNCTION CHANGE WITH AGING: CROSS- SECTIONAL VERSUS LONGITUDINAL ANALYSIS.
[13C]-NAPROXEN BREATH TEST AS THE PREDICTOR OF NAPROXEN-INDUCED GASTRIC MUCOSAL INJURY.
COMPARISON OF TRIPLE THERAPY WITH RABEPRAZOLE, METRONIDAZOLE AND SITAFLOXACIN THERAPY VERSUS TRIPLE THERAPY WITH RABEPRAZOLE, AMOXICILLIN AND SITAFLOXACIN THERAPY AS THE 3RD RESCUE REGIMEN FOR ERADICATION OF H. PYLORI.
COMPARISON OF FUNCTIONAL CYP2A6 POLYMORPHISMS AMONG THREE ASIAN POPULATIONS.
EFFECTS OF CYP2C19 AND CYP3A5 GENETIC POLYMORPHISMS ON THE DISPOSITION OF CILOSTAZOL AND ITS ACTIVE METABOLITES AND PLATELET AGGREGATION AT STEADY STATE.
STEM CELL INTERVENTION AT PRE-SYMPTOMATIC STAGE PREVENTS OVERT HEART FAILURE SYNDROME IN GENETIC CARDIOMYOPATHY.
PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF TOCILIZUMAB (TCZ) IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA).
ASSOCIATION OF INFLIXIMAB CLEARANCE AND RESTING ENERGY EXPENDITURE IN CHILDREN.
AN INTEGRATED APPROACH TO DEVELOP BELATACEPT DOSING REGIMENS FOR PHASE 3 STUDIES IN RENAL TRANSPLANT SUBJECTS.
REVIEW OF TRANSPORTER-RELATED POST-MARKETING REQUIREMENT (PMR)/POST-MARKETING COMMITMENT (PMC) STUDY REPORTS.
INTERACTION BETWEEN GENETIC VARIANTS IN THE TRANSPORTERS, OCT1 AND MATE1, AND GLYCEMIC RESPONSE TO METFORMIN.
EFFECT OF RIFAMPIN INDUCTION ON THE GLUCOSELOWERING EFFECT OF METFORMIN AND OCT1 MRNA LEVELS IN HEALTHY PARTICIPANTS.
CONTRIBUTION OF OATP1B-TYPE CARRIERS TO CISPLATIN DISPOSITION AND TOXICITY.
CONTROLLED-RELEASE LOW-DOSE PHENTERMINE/ TOPIRAMATE (PHEN/TPM CR) REDUCES WEIGHT, IMPROVES GLYCEMIC MARKERS, AND DECREASES PROGRESSION TO TYPE 2 DIABETES MELLITUS (T2DM) IN OVERWEIGHT AND OBESE PATIENTS WITH OBESITY-RELATED COMORBIDITIES.
MAGNITUDE OF WEIGHT LOSS CONFERRED BY CONTROLLED- RELEASE LOW-DOSE PHENTERMINE/TOPIRAMATE (PHEN/TPM CR) DETERMINES EXTENT OF CARDIOMETABOLIC BENEFIT.
LOW-DOSE CONTROLLED-RELEASE PHENTERMINE/ TOPIRAMATE (PHEN/TPM CR) RESULTS IN SIGNIFICANT WEIGHT LOSS AND IMPROVES ATHEROSCLEROTIC BIOMARKERS IN OVERWEIGHT/OBESE PATIENTS WITH OBESITYRELATED COMORBIDITIES.
FLEXIBLE MANUFACTURE AND ADAPTIVE PROTOCOLS: EMPOWERING FIRST IN HUMAN STUDIES.
INVESTIGATION OF POSSIBLE FORMULATION EFFECT ON DIGOXIN ABSORPTION.
DEVELOPMENT OF A PUBLIC DRUG TRANSPORTER DATABASE.
RELEVANCE AND VALUE OF IN VITRO P-GP INHIBITION DATA FOR NEW MOLECULAR ENTITIES.
A COMPARISION OF CG AND MDRD EQUATIONS FOR DOSAGE ADJUSTMENT IN RENAL IMPAIRMENT.
DIFFERENTIAL EFFECTS OF HEPATIC INSUFFICIENCY ON SENSITIVE CYP SUBSTRATES.
CAN GREATER THAN 85% RECOVERY IN MASS BALANCE 14C OR 3H HUMAN MACROTRACER ABSORPTION, METABOLISM, AND EXCRETION (AME) STUDIES BE ACHIEVED?
PROTECTIVE EFFECT OF AMIODARONE AGAINST CARDIAC EFFECTS OF MISTAKEN THYROID SUPPLEMENTATION DURING HYPERTHYROIDISM.
MONITORING AMIODARONE THERAPY IN ATRIAL FIBRILLATION CLINIC PRODUCES HIGH EFFICACY AND LOW TOXICITY RATES.
INVESTIGATING ETHNIC DIFFERENCES IN QTCF RESPONSE TO MOXIFLOXACIN IN A RANDOMIZED, DOUBLEBLIND STUDY.
DRUG ABUSE POTENTIAL OF DIMEBON: A RANDOMIZED, DOUBLE-BLIND, SINGLE-DOSE PLACEBO- AND ACTIVECONTROLLED CROSSOVER STUDY IN HEALTHY RECREATIONAL POLYDRUG USERS.
BEERS RESTRICTED DRUG USE IN GERIATRIC HEMATOLOGY/ ONCOLOGY PATIENTS.
USE OF PHARMACOLOGY, BIOLOGY, AND DISEASE/ GENE NETWORKS TO ADVANCE MECHANISM FOR CLINICALLY OBSERVED ADVERSE EVENTS.
THE SAFETY, TOLERABILITY, AND PHARMACOKINETIC AND PHARMACODYNAMIC PROFILES OF HM10560A, A SUSTAINED- RELEASE HUMAN RECOMBINANT GROWTH HORMONE IN HEALTHY MALE VOLUNTEERS.
RESVERATROL SUPPRESSED STEM-LIKE PROPERTY AND ENHANCED RADIOSENSITIVITY IN GLIOBLASTOMA CD133-POSITIVE CELLS BY INHIBITION OF IL-6/STAT3 AXIS.
IN VIVO CYP3A-ACTIVITY IS SIGNIFICANTLY LOWER IN CYCLOSPORINE THAN IN TACROLIMUS TREATED RENAL TRANSPLANT RECIPIENTS.
THE CYP3A5 GENOTYPE HAS A MARKED IMPACT ON TACROLIMUS PHARMACOKINETICS BUT DOES NOT AFFECT MIDAZOLAM PHARMACOKINETICS IN A LARGE COHORT OF RENAL TRANSPLANT RECIPIENTS.
SIMULTANEOUS EVALUATION OF THE IMPACT OF AZOLES ON IN VIVO CYP3A ACTIVITY AND CALCINEURIN INHIBITOR PHARMACOKINETICS IN RENAL TRANSPLANT RECIPIENTS: A PILOT STUDY.
CYP2C9 GENOTYPE AND DOSE OPTIMIZATION OF CELECOXIB, A SELECTIVE COX-2 INHIBITOR, IN HEALTHY KOREANS.
DOSE ADJUSTMENT OF ATOMOXETINE BASED ON CYP2D6 GENOTYPE IN HEALTHY KOREANS.
A COMMON CNR1 (CANNABINOID RECEPTOR 1) HAPLOTYPE ATTENUATES THE DECREASE IN HDL CHOLESTEROL THAT TYPICALLY ACCOMPANIES WEIGHT GAIN.
PHENOTYPIC VERSUS GENOTYPIC DATA TO PREDICT WARFARIN RESPONSE.
KCNJ1 SNPS ARE ASSOCIATED WITH INCREASED FASTING GLUCOSE AND RISK OF NEW ONSET DIABETES DURING HCTZ THERAPY.
SORAFENIB IS AN INHIBITOR OF UGT1A1 BUT IS METABOLIZED BY UGT1A9: IMPLICATIONS OF UGT1A GENETIC VARIANTS ON SORAFENIB EXPOSURE AND SORAFENIBINDUCED HYPERBILIRUBINEMIA.
PHARMACOGENOMICS OF CYCLOPHOSPHAMIDE.
UGT1A9, UGT2B7 and MRP2 GENOTYPES CAN EXPLAIN INTER-INDIVIDUAL DIFFERENCES IN MYCOPHENOLIC ACID EXPOSURE IN PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS.
GENETIC VARIATION IS ASSOCIATED WITH CALCINEURIN INHIBITOR (CNI) RELATED NEPHROTOXICITY: RESULTS FROM A MULTICENTER CONSORTIUM.
EFFECT OF A FUNCTIONAL POLYMORPHISM IN ORGANIC ANION TRANSPORTER 3, OAT3, ON THE DISPOSITION OF CEFOTAXIME IN ASIAN POPULATION.
DEVELOPMENT OF PHARMACOGENOMIC RESEARCH DATABASE: INTEGRATION AND AGGREGATION MULTIDISCIPLINARY DATA.
LACK OF A DRUG-DRUG INTERACTION OF A CYCLIN DEPENDENT KINASE (CDK) INHIBITOR WITH APREPITANT.
REGIMEN SELECTION FOR FOLFIRI AND FOLFOX BASED ON UGT1A1 GENOTYPE AND PHYSICAL BACKGROUND IS FEASIBLE IN JAPANESE PATIENTS WITH ADVANCED COLORECTAL CANCER.
FOLATE INTAKE AND THE INCIDENCE OF COLORECTAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS.
COMPARISON OF THE PHARMACOKINETICS OF TIVOZANIB IN ONCOLOGY SUBJECTS COMPARED WITH HEALTHY VOLUNTEERS.
N-ACETYLCYSTEINE AS A NOVEL PROPHYLACTIC TREATMENT FOR IFOSFAMIDE INDUCED NEPHROTOXICITY; TRANSLATIONAL PHARMACOKNETICS AND CASE REPORTS.
CYCLOOXYGENASE-2 (COX-2) AND IMPAIRED RESPONSE TO ASPIRIN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.
PREDICTING THE PHARMACOKINETICS (PK) OF THEOPHYLLINE (THEO) AND ITS INTERACTION WITH FLUVOXAMINE (FLUV) IN LIVER CIRRHOSIS (CIRR).
THE IMPACT OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN AORTIC VALVE DISEASE. D.
NON-DIPPING PATTERN AND ENDOTHELIAL DYSFUNCTION ARE ASSOCIATED WITH UNCONTROLLED BLOOD PRESSURE IN RESISTANT HYPERTENSION.
PHARMACOKINETICS AND DISPOSITION OF [14C]-LURASIDONE IN HUMAN.
MECHANISM-BASED POPULATION PHARMACOKINETIC MODELING OF MDMA IN HUMANS.
EVALUATION OF THE PERFORMANCE OF PEDIATRIC OTC MONOGRAPH DOSING GUIDANCE FOR GUAIFENESIN VIA SIMULATION.
EVALUATION OF THE PERFORMANCE OF PEDIATRIC OTC MONOGRAPH DOSING GUIDANCE FOR DOXYLAMINE VIA POPULATION PHARMACOKINETIC MODELING AND SIMULATION.
EVALUATION OF THE PERFORMANCE OF PEDIATRIC OTC MONOGRAPH DOSING GUIDANCE FOR CHLORPHENIRAMINE VIA POPULATION PHARMACOKINETIC MODELING AND SIMULATION.
EVALUATION OF THE PERFORMANCE OF PEDIATRIC OTC MONOGRAPH DOSING GUIDANCE FOR PSEUDOEPHEDRINE VIA POPULATION PHARMACOKINETIC MODELING AND SIMULATION.
ASSOCIATION OF GENETIC POLYMORPHISMS OF UGT1A8, UGT1A9, SLCO1B3 AND ABCC2/ABCG2 ON PHARMACOKINETICS OF MYCOPHENOLIC ACID IN CHINESE.
POPULATION PK ANALYSIS OF INTRAVENOUS CXA-101 IN SUBJECTS WITH COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS.
DAVUNETIDE PHARMACOKINETICS IN PLASMA AND CSF OF ALZHEIMER's PATIENTS AND HEALTHY VOLUNTEERS.
AN INTEGRATED POPULATION PHARMACOKINETIC MODEL FOR A FIRST-IN-CLASS HER2 TARGETED ANTIBODYDRUG CONJUGATE TRASTUZUMAB-DM1 (T-DM1): SIMULTANEOUS MODELING OF T-DM1 AND TOTAL TRASTUZUMAB PHARMACOKINETICS IN HEAVILY PRETREATED HER2+ METASTATIC BREAST CANCER PATIENTS.
CLINICAL IMPLICATION OF POPULATION PHARMACOKINETICS OF DROZITUMAB, A HUMAN MONOCLONAL ANTIBODY TARGETING DEATH RECEPTOR 5, IN PATIENTS WITH SOLID TUMORS.
COMPARISON OF METABOLISM OF ACETAMINOPHEN IN JAPANESE AND HAN CHINESE HEALTHY SUBJECTS.
EFFECT OF NEOMYCIN ON THE PHARMACOKINETICS (PK) OF SORAFENIB (S).
CYP2C9 PHENOTYPING USING A SINGLE-POINT DRIED BLOOD SPOT AFTER ORAL ADMINISTRATION OF FLURBIPROFEN.
POPULATION K-PD MODEL OF SODIUM NITROPRUSSIDE IN CHILDREN.
[14C]-RG7128 IS EXTENSIVELY CONVERTED TO THE CYTIDINE NUCLEOSIDE ANALOG PSI-6130: ADME RESULTS FOLLOWING A SINGLE ORAL DOSE TO HEALTHY MALE SUBJECTS.
MINIMAL BLOOD VOLUME SAMPLE STRATEGIES FOR THERAPEUTIC DRUG MONITORING OF PAIN MEDICATIONS IN SMALL CHILDREN.
RITONAVIR INHIBITS PRASUGREL IN VITRO BIOACTIVATION: A POTENTIAL PHARMACOKINETIC DRUG-DRUG INTERACTION.
POPULATION PHARMACOKINETICS OF RISPERIDONE USING SPARSE AND D-OPTIMAL SAMPLING IN CHILDREN.
PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF SINGLE SUBCUTANEOUS (SC) DOSES OF TOCILIZUMAB (TCZ) ADMINISTERED WITH AND WITHOUT rHuPH20, A RECOMBINANT HUMAN HYALURONIDASE, IN HEALTHY VOLUNTEERS.
INHIBITORY EFFECTS OF COMMONLY USED HERBAL EXTRACTS ON UGT1A4, 1A6, AND 1A9 ENZYME ACTIVITIES.
LIMITATIONS OF LIMITED SAMPLING STRATEGY (LSS) FOR ESTIMATION OF OMEPRAZOLE (OME)-TO-5-HYDROXYOMEPRAZOLE (5OH) AREA UNDER THE CONCENTRATION TIME CURVE RATIO (AUCOME/AUC5OH) IN CYTOCHROME P450 (CYP) 2C19 EXTENSIVE METABOLIZERS (EMs).
EXPOSURE-RESPONSE ANALYSIS IN PATIENTS WITH HER2- POSITIVE (HER2+) METASTATIC BREAST CANCER (MBC) TO ASSESS THE EFFECT OF T-DM1 ON QTC PROLONGATION.
TARGET-MEDIATED POPULATION PHARMACOKINETICS OF AN ANTI-TWEAK MONOCLONAL ANTIBODY IN RHEUMATOID ARTHRITIS PATIENTS.
IMMUNOGENICITY AND SAFETY OF A SINGLE INTRAMUSCULAR DOSE OF A DIPHTHERIA-TETANUS TOXOID (TD) VACCINE (GC1107) IN KOREAN ADULTS.
EVALUATION OF OPTIMAL DOSING REGIMENS FOR INVESTIGATIONAL DRUG MLN8237, AN AURORA A KINASE INHIBITOR, IN COMBINATION WITH DOCETAXEL THROUGH PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODELING OF HEMATOLOGICAL TOXICITY.
ASSESSMENT OF PHARMACOKINETIC AND SAFETY INTERACTIONS BETWEEN CG100649, A NOVEL NON-STEROIDAL ANTI-INFLAMMATORY DRUG, AND KETOCONAZOLE IN HEALTHY VOLUNTEERS.
POPULATION PHARMACOKINETICS OF TACROLIMUS IN CHILDREN DURING FOURTEEN DAYS FOLLOWING LIVER TRANSPLANTATION.
COMPARISON OF THE PHARMACOKINETIC AND PHARMACODYNAMIC CHARACTERISTICS OF HL-018 (METFORMIN ACETATE) VERSUS GLUCOPHAGE®.
POPULATION ANALYSIS OF FUNCTIONAL ACTIVITIES QUESTIONNAIRE (FAQ) IN THE ADNI (ALZHEIMER's DISEASE NEUROIMAGING INITIATIVE) DATABASE.
POPULATION PHARMACOKINETICS OF MODAFINIL AND ITS ACID AND SULFONE METABOLITES IN CHINESE MALES.
TRANSLATIONAL PHARMACOKINETICS AND PHARMACODYNAMICS OF AN FCRN VARIANT OF AN ANTI-CD4 MONOCLONAL ANTIBODY FROM PRECLINICAL MODEL TO PHASE I STUDY.
LIMITED SAMPLING STRATEGIES (LSS) TO PREDICT OMEPRAZOLE TO OMEPRAZOLE SULFONE (OME/SULF) AUClast RATIO AS A BIOMARKER OF CYTOCHROME P450 (CYP) 3A ACTIVITY IN CYP2C19 EXTENSIVE METABOLIZERS (EMs).
THE EFFECT OF CLADRIBINE TABLETS ON RELAPSE RATE DYNAMICS: REPEATED TIME-TO-EVENT ANALYSIS.
GRAPEFRUIT JUICE INCREASES SYSTEMIC EXPOSURE OF LOPERAMIDE WITHOUT CONSEQUENT CENTRAL NERVOUS SYSTEM OPIATE-LIKE EFFECTS IN HEALTHY VOLUNTEERS.
PROBABILITY-BASED MANN-WHITNEY EFFECT CONCEPT AND ITS APPLICATION TO DOSE-RESPONSE ASSESSMENT.
FIXED DOSING VERSUS BODY SIZE-BASED DOSING OF ANTICANCER DRUGS IN ADULTS: A POPULATION PHARMACOKINETIC APPROACH.
EXPOSURE-RESPONSE ANALYSES TO SUPPORT DOSE SELECTION OF BMS-936557, A MONOCLONAL ANTIBODY TO IP-10, FOR A PHASE 2B STUDY IN PATIENTS WITH ULCERATIVE COLITIS.
THE GUINEA PIG EXPRESSES MDR1, CAR AND PXR AND REPRESENTS A VERY GOOD MODEL FOR STUDYING DRUG METABOLISM.
COMPARTMENTAL ANALYSIS OF URSODIOL PK IN NEONATES USING AMS.
THE EFFECT OF ANTICHOLINERGIC BURDEN ON FUNCTIONAL OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE DEMENTIA.
EVIDENCE THAT MEGALIN-MEDIATED ENDOCYTOSIS IS INVOLVED IN THE PLACENTAL TRANSPORT OF AMINOGLYCOSIDES.
DRUG INFORMATION SERVICE IN EXTREME POLYPHARMACY.
ONE YEAR PROSPECTIVE STUDY ON ANTIBIOTIC RESISTANCE OF E.COLI URINE ISOLATES OBTAINED FROM PATIENTS HOSPITALIZED AT THE DEPARTMENT OF NEPHROLOGY OF A UNIVERSITY PEDIATRIC HOSPITAL IN NOVI SAD, SERBIA.
DRUG INFORMATION SERVICE FOR NONAGENARIAN.
PREDICTION OF THE INCREASE IN SYSTEMIC EXPOSURE OF PAROXETINE IN PATIENTS WITH RENAL IMPAIRMENT.
DRUG INFORMATION SERVICE FOR ELDERLY PATIENTS.
PREDICTION OF DRUG CLEARANCE IN A SMOKING POPULATION: MODELING THE IMPACT OF VARIABLE CIGARETTE CONSUMPTION ON INDUCTION OF CYP1A2.
QUANTITATIVE PK/PD TRANSLATION OF PRECLINICAL BIOMARKER RESPONSE TO CLINICAL PROOF OF MECHANISM (POM) RESPONSE, A CASE STUDY WITH A KAPPA OPIOID RECEPTOR (KOR) ANTAGONIST.
BAYESIAN MONTE CARLO MARKOV CHAIN (MCMC) TWOSTAGE (TS) APPROACHES ON NON-LINEAR MIXED-EFFECT PHARMACOKINETIC MODELS.
CLINICAL TRIAL SIMULATION TO EVALUATE POTENTIAL DRIFTS IN TYPE I ERROR WHEN A POPULATION ENRICHMENT STRATEGY IS USED TO IMPROVE EFFICIENCY OF PLACEBO-CONTROLLED CLINICAL TRIAL IN DEPRESSION.
GENETIC MARKERS ASSOCIATED WITH PLATINUM/ TAXANES INDUCED GASTROINTESTINAL TOXICITY IN SCOTROC1 TRIAL.
PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD) AND EXPOSURE-PD RELATIONSHIPS OF THE INVESTIGATIONAL DRUG MLN8237, AN AURORA A KINASE INHIBITOR IN PATIENTS WITH ADVANCED SOLID TUMORS.
GENETIC POLYMORPHISMS RELATED TO PACILTAXELINDUCED CYTOTOXICITY IN LYMPHOBLASTOID CELL LINES AND OVERALL SURVIVAL IN LUNG CANCER PATIENTS AFTER PACLITAXEL-BASED CHEMOTHERAPY.
EFFECT OF GEMCITABINE PATHWAY GENETIC POLYMORPHISMS ON OVERALL SURVIVAL OF NON-SMALL CELL LUNG CANCER TREATED WITH GEMCITABINE.
EXPLORATORY IND STUDY OF A CNS DRUG: PILOT STUDY TO ESTABLISH MICRODOSING STRATEGY USING POSITRON EMISSION TOMOGRAPHY AFTER SERTRALINE ADMINISTRATION IN HEALTHY VOLUNTEERS.
CAN NARROW THERAPEUTIC WINDOWS BE ACHIEVED IN WARAFARIN DRUG-DRUG INTERACTION TRIALS?
SERIOUS ADVERSE EVENTS IN EARLY DRUG DEVELOPMENT: RESULTS FROM A 6-YEAR SURVEY CONDUCTED IN FRANCE BY THE CLUB PHASE 1.
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY IN HEALTHY MALE SUBJECTS TO ASSESS THE EFFECT OF SUBANAESTHETIC INTRAVENOUS DOSES OF KETAMINE UPON NEUROCOGNITIVE FUNCTIONS.
DRUG-DRUG INTERACTIONS (DDIS) YIELDING TO MORE THAN 20-FOLD INCREASE IN SUBSTRATE EXPOSURE: A LITERATURE REVIEW USING THE UNIVERSITY OF WASHINGTON M&T DRUG INTERACTION DATABASE©.
"INTELLIGENT" AUTOMATED ECG EXTRACTION FROM CONTINUOUS 12-LEAD HOLTER RECORDINGS REDUCES MEASUREMENT VARIABILITY IN THOROUGH QT STUDIES.
THE FIRST ORALLY ADMINISTERED LOW MOLECULAR WEIGHT LH AGONIST IS WELL-TOLERATED AND DISPLAYS NON-DOSE PROPORTIONAL. PHARMACOKINETICS.
DEVELOPMENT AND CLINICAL TESTING OF LIPID BASED FORMULATIONS TO ENHANCE ORAL BIOAVAILABILITY OF A BCS CLASS II DRUG.
A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF VIGABATRIN FOR METHAMPHETAMINE DEPENDENCE.
TOLERABILITY OF DONEPEZIL 23MG TABLETS IN HEALTHY SUBJECTS.
THE EFFECT OF AGE ON THE PHARMACOKINETICS OF FIMASARTAN (BR-A-657).
COMPARISON OF THE PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF ENTERIC-COATED TRIFLUSAL AND TRIFLUSAL IN HEALTHY MALE SUBJECTS.
EVALUATION OF THE SINGLE-DOSE PHARMACOKINETICS OF LU AA21004 AND ITS METABOLITES IN SUBJECTS WITH AND WITHOUT HEPATIC IMPAIRMENT.
EVALUATION OF THE EFFECTS OF LU AA21004 ON CARDIAC REPOLARIZATION IN HEALTHY ADULT MALE SUBJECTS.
IMPLICATIONS OF NONSUSTAINED VENTRICULAR TACHYCARDIA (NSVT) IN HEALTHY SUBJECTS IN CLINICAL TRIALS.
A RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS SERUM TRANSAMINASE ELEVATIONS AND ANTIBODY FORMATION FOLLOWING REPEAT SUBCUTANEOUS DOSING OF LMWH, UFH OR THE NOVEL ANTICOAGULANT M118 IN HEALTHY VOLUNTEERS.
EFFECT OF GENETIC VARIATION IN THE ORGANIC CATION TRANSPORTER 1 AND 2 ON METFORMIN PHARMACOKINETICS: NONLINEAR MIXED EFFECTS ANALYSIS.
ASSOCIATION OF T-786C ENDOTHELIAL NITRIC OXIDE SYNTHASE (NOS3) POLYMORPHISM WITH LACK OF BLOOD PRESSURE CONTROL AND INCREASED TOTAL PERIPHERAL RESISTANCE IN PATIENTS IN ANTIHYPERTENSIVE DRUG THERAPY.
HUMAN HAIR FOLLICLES AS A CLINICAL SAMPLE SOURCE FOR GENE EXPRESSION PROFILING BY MICROARRAY ANALYSIS.
GENETIC VARIATION AND COGNITIVE FUNCTION IN OLDER ADULTS.
ARE SINGLE NUCLEOTIDE POLYMORPHISMS OF CYP2C9 A RISK FACTOR FOR NSAID-ASSOCIATED ADVERSE EVENTS?
INFLUENCE OF G PROTEIN RECEPTOR KINASE 4 (GRK4) POLYMORPHISMS ON BLOOD PRESSURE RESPONSE TO THE β-BLOCKER ATENOLOL.
17-HYDROEXEMESTANE: A POTENT INHIBITOR OF CYP19 AND SUBSTRATE OF CYP3A.
PATHWAY-BASED PHARMACOGENOMICS OF GEMCITABINE PHARMACOKINETICS IN PATIENTS WITH SOLID TUMORS.
CHARACTERIZATION OF A HUMAN LIVER BANK AS A TOOL FOR RESEARCH IN PHARMACOGENETICS (PGx).
ABCB1 POLYMORPHISMS ARE ASSOCIATED WITH TARIQUIDAR- INDUCED INCREASES IN DOCETAXEL HALF-LIFE.
GENOME-WIDE APPROACH TO GENERATE A GENETIC SIGNATURE PREDICTIVE OF PACLITAXEL RESPONSE.
GENETIC RISK FACTORS FOR TYPE 2 DIABETES MELLITUS AND RESPONSE TO SULFONYLUREA TREATMENT.
ASSOCIATION BETWEEN DOPAMINE D3 RECEPTOR GENOTYPE AND RESPONSE TO A DOPAMINE D3 RECEPTOR ANTAGONIST IN SCHIZOPHRENIC SUBJECTS.
METHIONINE ADENOSYLTRANSFERASE 2A AND 2B PHARMACOGENETICS: GENE SEQUENCE VARIATION AND FUNCTIONAL STUDIES.
A DRUG-DRUG INTERACTION STUDY BETWEEN ROSUVASTATIN AND PANTOPRAZOLE AFTER ORAL ADMINISTRATION IN HEALTHY MALE SUBJECTS.
GENETIC VARIANTS OF THE ORGANIC CATION TRANSPORTER, OCT1, IDENTIFIED BY THE 1000 GENOMES PROJECT EXHIBIT ALTERED FUNCTION AND CELLULAR LOCALIZATION.
ASSOCIATION BETWEEN CYP2C9 PROMOTER REGION VARIANTS AND WARFARIN DOSE REQUIREMENTS IN AFRICAN AMERICANS.
A POPULATION PHARMACOKINETIC (PK)-PHARMACODYNAMIC (PD) ANALYSIS OF AXITINIB (AG-013736) EFFICACY AND TOLERABILITY ENDPOINTS IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC).
SINGLE AND MULTIPLE-DOSE IV AND ORAL PHARMACOKINETICS (PK) OF THE HEDGEHOG PATHWAY INHIBITOR GDC-0449 DURING A PHASE 1 STUDY IN HEALTHY FEMALE SUBJECTS.
CONCURRENT USE OF PROTON PUMP INHIBITORS (PPI) OR H2-BLOCKERS DID NOT ADVERSELY AFFECT NILOTINIB RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML).
EXPRESSION OF CYP450 MRNAS IN CANCER STEM CELLS ISOLATED FROM VARIOUS BREAST CANCER CELL LINES.
ONCOLOGY POPULATION PROFILE FOR SIMCYP PHARMACOKINETIC (PK) PREDICTIONS.
TWO BIOMARKERS OF METABOLIC SYNDROME, LEPTIN AND INTERLEUKINE-6, DECREASE CYP3A EXPRESSION AND ACTIVITY IN HEPARG CELLS.
ADIPONECTINE, A BIOMARKER OF METABOLIC SYNDROME, LIKELY MODULATES CYP3A4-MEDIATED DRUG DISPOSITION.
EFAVIRENZ INDUCES CYP2C19-MEDIATED HYDROXYLATION AND CYP3A4-CATALYZED SULFOXIDATION OF OMEPRAZOLE.
EFFECTS OF EFAVIRENZ ON THE STEREOSELECTIVE METABOLISM OF OMEPRAZOLE IN HEALTHY SUBJECTS.
POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF THE PAN-PHOSPHOINOSITIDE-3 KINASE (PI3K) INHIBITOR GDC-0941 IN PHASE I PATIENTS WITH ADVANCED SOLID TUMORS.
POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF THE DUAL PI3K/MTOR INHIBITOR GDC-0980 IN PHASE I PATIENTS WITH ADVANCED SOLID TUMORS.
LACK OF PHARMACOKINETIC INTERACTIONS BETWEEN ASP1941, A SELECTIVE SODIUM GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITOR, AND SITAGLIPTIN IN HEALTHY SUBJECTS.
LACK OF PHARMACOKINETIC INTERACTIONS BETWEEN ASP1941, A SELECTIVE SODIUM GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITOR, AND PIOGLITAZONE IN HEALTHY SUBJECTS.
EXPOSURE-RESPONSE MODELING OF DIZZINESS, THE DOSE-LIMITING ADVERSE EVENTS IN A FTIH STUDY OF A NEW GLYCINE TRANSPORTER1 INHIBITOR USING A MARKOV MIXED-EFFECTS MODEL.
LONGITUDINAL EXPOSURE-RESPONSE META-ANALYSIS OF THE EFFECT OF CALCIUM CHANNEL MODULATORS ON DIGIT SYMBOL SUBSTITUTION TEST IN HEALTHY VOLUNTEERS AND APPLICATION IN A NOVEL THERAPEUTIC AREA.
PHARMACOKINETICS, TOLERABILITY, AND SAFETY OF THE DUAL ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN IN JAPANESE AND CAUCASIAN HEALTHY SUBJECTS.
COMPARATIVE SYSTEMIC PHARMACOKINETICS (PK) OF BETA-LACTAM ANTIBIOTICS (BLAS) IN HUMANS- EFFECTS OF PHYSICOCHEMICAL (PC) PROPERTIES.
DISPOSITION OF 5-HYDROXYMETHYLFURFURAL (5-HMF) IN HUMAN BLOOD - CONCURRENT HEMOGLOBIN (Hb) BINDING AND METABOLISM IN RED BLOOD CELLS (RBC).
ORAL PHARMACOKINETICS OF STD07 IN HEALTHY VOLUNTEERS IN A PHASE I CLINICAL PHARMACOLOGY STUDY.
LIMITED SAMPLING STRATEGIES FOR THE ESTIMATION OF RALTEGRAVIR DAILY EXPOSURE IN HIV-INFECTED PATIENTS.
CLINICAL TRIAL SIMULATION TO INFORM PHASE 2: COMPARISON OF DISTRIBUTED VERSUS CONCENTRATED PHASE 1 STUDY DESIGNS.
PHARMACOKINETICS AND PHARMACODYNAMICS OF THE SELECTIVE PROSTACYCLIN RECEPTOR AGONIST SELEXIPAG DURING AN UP-TITRATION REGIMEN OVER A WIDE DOSE RANGE IN HEALTHY MALE SUBJECTS.
IMPORTANCE OF ACID INHIBITION FOR GASTROESOPHAGEAL REFLUX DISEASE WITH LOW-DOSE ASPIRIN.
THE EFFECTS OF GENETIC POLYMORPHISMS OF ADH1B AND ALDH2 ON PHARMACOKINETICS OF ETHANOL.
RANDOMIZED, OPEN-LABEL, 2-WAY CROSSOVER STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF OVERENCAPSULATED VERSUS NON-OVER-ENCAPSULATED MOXIFLOXACIN IN HEALTHY SUBJECTS.
THE PHARMACOKINETICS OF YM150, AN ORAL DIRECT FACTOR XA INHIBITOR, EXHIBITS DOSE PROPORTIONALITY WITH NO CLINICALLY RELEVANT EFFECT OF ETHNICITY OR GENDER.
YM150, AN ORAL DIRECT FACTOR XA INHIBITOR, DOES NOT IMPACT THE STEADY-STATE PHARMACOKINETICS OF DIGOXIN FOLLOWING CO-ADMINISTRATION.
EFFECTS OF ORALLY ADMINISTERED IBUPROFEN AND ORALLY AND TOPICALLY ADMINISTERED DICLOFENAC ON THE PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE OF FUROSEMIDE, A LOOP DIURETIC.
POPULATION PHARMACOKINETIC (PK) MODELING OF CONATUMUMAB (CON) IN CANCER PATIENTS (PTS).
POPULATION PHARMACOKINETICS MODEL AND PEDIATRIC DOSE RECOMMENDATION FOR IV SILDENAFIL IN PULMONARY ARTERIAL HYPERTENSION.
PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF A SUPRA-THERAPEUTIC DOSE OF CETRORELIX PAMOATE IN HEALTHY MALES.
INVESTIGATION OF THE POTENTIAL FOR PK INTERACTIONS BETWEEN LY2216684, A NOREPINEPHRINE REUPTAKE INHIBITOR, AND SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTIDEPRESSANTS IN HUMANS.
PHARMACOKINETICS AND TOLERABILITY OF THE ORAL SELECTIVE PROSTACYCLIN RECEPTOR AGONIST SELEXIPAG AFTER MULTIPLE-DOSE ADMINISTRATION IN HEALTHY MALE SUBJECTS.
SEMI-MECHANISTIC POPULATION PHARMACOKINETIC MODEL OF MULTIVALENT TRASTUZUMAB-DM1 (T-DM1) IN PATIENTS WITH METASTATIC BREAST CANCER.
THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF RIDAFOROLIMUS (AP23573; MK-8669).
THE EFFECT OF MULTIPLE DOSES OF BOTH RIFAMPIN AND KETOCONAZOLE ON THE SINGLE DOSE PHARMACOKINETICS OF RIDAFOROLIMUS.
POPULATION PK AND EXPOSURE-RESPONSE ANALYSES OF APREMILAST IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS.
ASSESSMENT OF THE PHARMACOKINETICS OF COADMINISTERED METFORMIN AND LOBEGLITAZONE, A NOVEL THIAZOLIDINEDIONE ANTIHYPERGLYCEMIC AGENT, IN HEALTHY VOLUNTEERS.
METABOLIC FATE AND PHARMACOKINETIC CHARACTERIZATION OF T-DM1: AN EMPHASIS ON PRECLINICAL AND CLINICAL CATABOLISM.
PHARMACOKINETICS (PK) OF QUETIAPINE FUMARATE XR (QFX) IN CHINESE PATIENTS (PTs) WITH SCHIZOPHRENIA (SCH).
PHARMACOKINETIC INTERACTION BETWEEN FIMASARTAN AND AMLODIPINE IN HEALTHY VOLUNTEERS.
PREDICTION OF AMG 479 EXPOSURES IN NON-PANCREATIC AND PANCREATIC CANCER (PC) PATIENTS.
PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF A NOVEL ACID PUMP ANTAGONIST, YH4808, IN HEALTHY VOLUNTEERS.
DANOPREVIR (DNV) DOES NOT CHANGE THE EFFECTS OF RITONAVIR (RTV) ON THE PHARMACOKINETICS (PK) OF CYTOCHROME P450 (CYP) 3A SUBSTRATE MIDAZOLAM (MDZ) AND 2C9 SUBSTRATE WARFARIN (WAR).
EVIDENCE OF ALTERED POSTNATAL MATURATION OF RENAL FUNCTION IN AMINOGLYCOSIDE-TREATED PRETERM NEWBORNS.
RDEA594, A NOVEL URAT1 INHIBITOR, SHOWS SIGNIFICANT ADDITIVE URATE LOWERING EFFECTS IN COMBINATION WITH FEBUXOSTAT IN BOTH HEALTHY SUBJECTS AND GOUT PATIENTS.
RDEA594, A NOVEL URICOSURIC AGENT, SHOWS SIGNIFICANT ADDITIVE ACTIVITY IN COMBINATION WITH ALLOPURINOL IN GOUT PATIENTS.
PHARMACOKINETICS AND SERUM URATE LOWERING EFFECT OF RDEA594, A NOVEL URAT1 INHIBITOR, IN GOUT PATIENTS AND SUBJECTS WITH VARYING DEGREES OF RENAL IMPAIRMENT.
THE EFFECT OF MILD TO MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF TASOCITINIB (CP- 690,550).
AN ASSESSMENT OF ADHERENCE TO THE NATIONAL POLICY OF ARTEMISININ-BASED COMBINATION THERAPY FOR THE TREATMENT OF MALARIA IN HOUSEHOLDS AND AMONG UNDER-FIVES AND PREGNANT WOMEN IN A SOUTHERN NIGERIAN CITY.
THE INCIDENCE OF CNS DEPRESSION OF NEONATES BREASTFED BY MOTHERS RECEIVING CODEINE FOR POSTPARTUM ANALGESIA.
A COMPARISON OF FOLIC ACID PHARMACOKINETICS IN OBESE AND NON-OBESE WOMEN OF CHILDBEARING AGE.